Scholarlink

<p>Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease characterized by the presence of antibodies specific to the aquaporins 4 (AQP4) protein. The complexity of its pathogenesis poses significant challenges to treatment, which remains both limited and costly. Consequently, there is an urgent need to elucidate the pathogenesis of NMOSD and to develop novel therapeutic strategies. Here, through a proteomic screen of serum from AQP4-IgG-positive NMOSD patients and a control cohort, we observed a significant downregulation of Insulin-like growth factor 2 (IGF-2) in the serum of AQP4-IgG-positive NMOSD patients and correlated with disease severity. Injecting adenovirus overexpressing IGF-2 into the brains of NMOSD mice reduced microglia, neuroinflammation, and brain injury. Both in vivo and in vitro experiments show IGF-2 activates the IGF-1R/PI3K/AKT pathway, reducing apoptosis and inflammation. These findings highlight IGF-2 as a promising target for NMOSD diagnosis and treatment, offering new insights into disease mechanisms and potential interventions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapeutic effects of IGF-2 on NMOSD by inhibiting astrocyte apoptosis through modulation of the IGF-1R/PI3K/AKT signaling pathway

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月27日

查看全文
  • Yingyu Zhang,
  • Na Xu,
  • Kaikai Yu,
  • Xiaoshuang Wang,
  • Xianhui Jiang,
  • Di Wang,
  • Qiurong Yang,
  • Yaxin Qu,
  • Shuai Wang,
  • Wensen Liu,
  • Xuemei Han

摘要

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease characterized by the presence of antibodies specific to the aquaporins 4 (AQP4) protein. The complexity of its pathogenesis poses significant challenges to treatment, which remains both limited and costly. Consequently, there is an urgent need to elucidate the pathogenesis of NMOSD and to develop novel therapeutic strategies. Here, through a proteomic screen of serum from AQP4-IgG-positive NMOSD patients and a control cohort, we observed a significant downregulation of Insulin-like growth factor 2 (IGF-2) in the serum of AQP4-IgG-positive NMOSD patients and correlated with disease severity. Injecting adenovirus overexpressing IGF-2 into the brains of NMOSD mice reduced microglia, neuroinflammation, and brain injury. Both in vivo and in vitro experiments show IGF-2 activates the IGF-1R/PI3K/AKT pathway, reducing apoptosis and inflammation. These findings highlight IGF-2 as a promising target for NMOSD diagnosis and treatment, offering new insights into disease mechanisms and potential interventions.